Evicenter
MarkdownMedical informationP&T meetings
AD109 (aroxybutynin-atomoxetine)

Obstructive sleep apnea

Also known as Oxnimbi
Manufacturer
Apnimed
Launch
Not announced
Last updated
183 sources

Executive summary

Conclusions

1 evidence topic · 29 sources

Summary
  • Regulatory status and timing: AD109 (proposed proprietary name Oxnimbi), a fixed-dose combination of aroxybutynin and atomoxetine, is under FDA review. The NDA was submitted through the section 505(b)(2) pathway in April 2026 and accepted in July 2026, with a PDUFA goal date of February 28, 2027; Fast Track designation for OSA was granted in May 2022. The third quarter 2026 Form 10-Q states that the FDA has raised questions regarding the adequacy of the NDA and has requested additional information, data, or analyses on the nonclinical, clinical, or CMC areas. No launch date was identified.
  • Primary efficacy (change in AHI4, hypopneas scored with at least 4% desaturation, from baseline to week 26, against placebo): in SynAIRgy (646 participants randomized), the difference was −4.0 events/h (95% CI −6.4 to −1.6; P = .001) under the treatment policy estimand, a geometric mean reduction of 44.1% against 17.6%, and −6.5 events/h (95% CI −8.8 to −4.3) under the on-treatment estimand, 55.6% against 19.1%. In LunAIRo (660 participants randomized), the difference was −4.08 events/h (95% CI −6.14 to −2.03; p <0.001) under the treatment policy estimand, 33.7% against 7.3%, and −5.81 events/h (95% CI −8.07 to −3.55) under the on-treatment estimand, 46.8% against 6.8%. The pooled treatment policy difference was −4.0 events/h (95% CI −5.6 to −2.5). The company topline releases report the on-treatment relative reductions (55.6% and 46.8%).
  • Secondary efficacy and patient-reported outcomes: at least 50% AHI reduction occurred in 25.8% against 19.8% in SynAIRgy (treatment policy; P = .182) and 28.5% against 16.0% in LunAIRo (treatment policy; p <0.001), and in 39.6% against 22.3% and 38.3% against 15.4% under the on-treatment estimand. Hypoxic burden decreased by 44.7% against 8.5% in SynAIRgy (treatment policy; nominal P <.0001) and by 37.4% against 10.0% in LunAIRo (treatment policy). PROMIS-Fatigue did not reach significance in SynAIRgy under the treatment policy estimand (P = .059), which ended formal hierarchical testing, and AD109 did not significantly reduce the PROMIS-Fatigue T-score under either estimand in LunAIRo; in the pooled on-treatment analysis, the differences were −0.48 for PROMIS-Fatigue (P = 0.27), −0.54 for PROMIS-Sleep Impairment (P = 0.26), and −0.18 for the Epworth Sleepiness Scale (P = 0.4).
  • Safety and discontinuation: in the SynAIRgy safety analysis set (325 AD109, 319 placebo), treatment-emergent adverse events occurred in 70.8% against 46.7%, including dry mouth (35.4% against 9.1%), insomnia (20.6% against 4.7%), nausea (11.4% against 0.6%), and urinary hesitation (8.9% against 0.3%); serious events occurred in 1.5% against 2.5%, and no deaths were reported. Treatment discontinuation due to adverse events was 21.2% against 3.1% in SynAIRgy, 23.7% against 6.6% by month 6 and 28.6% against 10.0% by month 12 in LunAIRo, and 25.0% (163/653) against 6.7% (43/646) by week 26 pooled. Overall treatment discontinuation was 35.2% against 15.5% by week 26 pooled and 46.5% against 25.1% at month 12 in LunAIRo. Heart rate of 100 beats/min or higher occurred in 6.3% against 1.9% in SynAIRgy (P = .006). The trials excluded clinically significant cardiovascular disease, blood pressure above 145/90 mmHg, and bothersome insomnia. Reported data from the open-label extension consist of a 2025 interim abstract (102 participants enrolled) that reports no adverse event data; the prospectus states the extension was completed in 2026.
  • Trial conduct and reporting: SynAIRgy protocol version 4.0 (December 15, 2023) and a 2025 LunAIRo congress abstract named the proportion of participants with at least 50% AHI reduction as the primary endpoint. SynAIRgy protocol version 6.0 (17 April 2025) and LunAIRo protocol amendment 4.0 (June 2025) reordered the primary and key secondary endpoints “to align with recent regulatory approvals for the treatment of OSA related to obesity”, after the registry primary completion dates of 2025-03-10 and 2025-05-07. LunAIRo has no full publication; its results come from congress abstracts, registry results first posted on 2026-11-03, company releases, and the prospectus. The on-treatment estimand included 260 and 296 participants in SynAIRgy and 240 and 293 in LunAIRo, against 302 and 313 and 324 and 326 in the treatment policy sets. A pooled abstract reports 39.0% against 18.8% with at least 50% AHI4 reduction without naming the estimand, and the prospectus labels the pooled 39% as on-treatment.
  • Clinical meaningfulness and outcome data: at the pre-NDA meeting, the FDA gave feedback on the clinical meaningfulness of certain endpoint results, including the primary endpoint, and on the limitations of the patient-reported outcomes, and indicated that additional analyses and justification may be needed; the company states that the FDA may determine the phase 3 results are not clinically meaningful to establish substantial evidence of effectiveness. An editorial states that the clinical significance of a placebo-adjusted reduction of about 4 events per hour is uncertain as a continuous measure, and that durability, long-term safety, and effects on cardiovascular events require further study. Neither phase 3 trial included an active comparator, and no head-to-head comparison of AD109 with another OSA treatment was identified. The company states the trials were not designed or powered to assess cardiovascular outcomes; the predicted reductions in cardiovascular events or all-cause mortality of 11.9% (treatment policy) and 19.2% (on-treatment) are modeled from pooled hypoxic burden reductions.
  • Studied population and place relative to current therapies: SynAIRgy and LunAIRo enrolled adults with mild to severe OSA who were intolerant of or refused PAP, with a BMI cap of 40 (men) or 42 (women) kg/m2; in the SynAIRgy intent-to-treat set of 615 participants, 411 (66.8%) had PAP intolerance and 205 (33.3%) PAP refusal, and in the pooled phase 3 population 51% had AHI below 20 events/h and 74% below 30. The VA/DoD 2025 guideline prescribes PAP as first-line therapy for severe OSA and PAP or a mandibular advancement device for an AHI of 5 to below 30, and suggests referral for hypoglossal nerve stimulation evaluation after PAP is unsuccessful or not accepted when the AHI is 15 or more; tirzepatide is indicated for moderate to severe OSA in adults with obesity. VA/DoD 2025 Recommendation 24 suggests against atomoxetine or a combination of atomoxetine and oxybutynin (“Weak against”), based on 2 randomized trials with mixed results and low confidence in the evidence; its evidence review ended on March 31, 2024, and Apnimed states that both phase 3 trials were completed in 2025. Apnimed intends to focus its initial launch on the approximately 10.5 million U.S. people diagnosed with OSA but untreated, a figure from a 2025 National Sleep Foundation survey, supported by Inspire Medical Systems, of 1,015 adults who reported their own diagnosis and treatment status.
  • Economic evidence: no price for AD109 has been published, and no cost-effectiveness analysis or budget impact model of AD109 was identified. The prospectus cites approximately 80 million people with OSA in the United States aged 30 to 69, from a study Apnimed commissioned from Clarivate; the published estimate by Apnimed and Clarivate authors reports 83.7 million U.S. adults aged 20 years and older with an AHI4 of 5 or more in 2024. Published analyses of current treatments report an incremental cost-effectiveness ratio of $15,915 per QALY gained for CPAP in moderate to severe OSA over a lifetime horizon in a Markov model and $39,471 per QALY for hypoglossal nerve stimulation in a 5-state Markov model.